What are the purchasing channels for Ensifentrine in Hong Kong?

Ohtuvayre (Ensifentrine)-ensefentine inhalation suspension is a new type of dual phosphodiesterase inhibitor that has the inhibitory function of both PDE3 and PDE4 and has unique pharmacological advantages. This compound mechanism enables exefantine to exhibit significant efficacy in the treatment of chronic obstructive pulmonary disease (COPD). COPD is a common chronic respiratory disease worldwide, mainly characterized by airflow limitation and persistent airway inflammation. Traditional treatment options mostly rely on bronchodilators and inhaled corticosteroids. The emergence of exefantine provides patients with another treatment approach that takes into account both bronchodilation and inflammation control.

The indications of this drug are mainly for adult patients with moderate to severe COPD, aiming to improve lung function, relieve symptoms of dyspnea, and reduce the frequency of acute exacerbations of the disease. Exefentine's dual PDE inhibitory effect not only expands airway smooth muscle, but also significantly inhibits the release of inflammatory mediators, thereby improving the overall environment and pathological state of the airway. Its rapid onset of action and good tolerability have been recognized in clinical studies, making it an effective supplement for patients with COPD, especially those who have insufficient response to traditional treatments.

IfOhtuvayre (Ensifentrine) can be approved by the local drug regulatory agency in Hong Kong and begin to enter the market circulation stage, patients can obtain the drug through a variety of formal channels. Specific purchase methods include purchasing from a qualified pharmacy after a prescription is issued by a specialized hospital or private clinic, or ordering through a medical service institution with legal import qualifications. As an international medical hub, it is equipped with a complete drug supervision system to ensure the drug quality and safety of Exefantine. At the same time, some international pharmaceutical direct mail platforms and overseas medical tourism institutions also provide patients with access. Patients should carefully choose formal channels and avoid purchasing counterfeit and substandard drugs to ensure treatment effectiveness and medication safety.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html